Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.

Shinichiro KashiwagiWakaba FukushimaYuka AsanoWataru GotoKoji TakadaSatoru NodaTsutomu TakashimaNaoyoshi OnodaMasahiko OhsawaKosei HirakawaMasaichi Ohira

Published in: BMC cancer (2017)

Our findings suggest that TLE3 is a useful marker for predicting the therapeutic effect of eribulin chemotherapy for TNBC.

Keyphrases

metastatic breast cancer
locally advanced
squamous cell carcinoma
randomized controlled trial
radiation therapy
clinical trial
phase iii